Fleury S.A. (FLRY3) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.050x

Based on the latest financial reports, Fleury S.A. (FLRY3) has a cash flow conversion efficiency ratio of 0.050x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$264.56 Million ≈ $51.91 Million USD) by net assets (R$5.28 Billion ≈ $1.04 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Fleury S.A. (FLRY3) liquidity interval to measure how many days the company can operate on defensive assets alone.

Fleury S.A. - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Fleury S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Fleury S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fleury S.A. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Guangdong Shenglu Telecommunication Tech Co Ltd
SHE:002446
-0.007x
EverCommerce Inc
NASDAQ:EVCM
0.045x
Dürr Aktiengesellschaft
F:DUE
0.117x
Isiklar Enerji ve Yapi Holding AS
IS:IEYHO
-0.116x
Semrush Holdings Inc
NYSE:SEMR
0.051x
Dianguang Explosion-proof Technology Co Ltd
SHE:002730
-0.019x
Shenzhen Batian Ecotypic Engineering Co Ltd
SHE:002170
0.028x
Tyra Biosciences Inc
NASDAQ:TYRA
-0.091x

Annual Cash Flow Conversion Efficiency for Fleury S.A. (2006–2025)

The table below shows the annual cash flow conversion efficiency of Fleury S.A. from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see FLRY3 stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 R$5.10 Billion
≈ $999.98 Million
R$1.57 Billion
≈ $308.32 Million
0.308x -14.16%
2024-12-31 R$5.37 Billion
≈ $1.05 Billion
R$1.93 Billion
≈ $378.80 Million
0.359x +27.54%
2023-12-31 R$5.11 Billion
≈ $1.00 Billion
R$1.44 Billion
≈ $282.42 Million
0.282x -22.94%
2022-12-31 R$2.70 Billion
≈ $530.00 Million
R$987.13 Million
≈ $193.69 Million
0.365x -33.47%
2021-12-31 R$1.85 Billion
≈ $363.88 Million
R$1.02 Billion
≈ $199.88 Million
0.549x +48.61%
2020-12-31 R$1.75 Billion
≈ $343.55 Million
R$647.14 Million
≈ $126.98 Million
0.370x -11.22%
2019-12-31 R$1.76 Billion
≈ $345.14 Million
R$732.32 Million
≈ $143.69 Million
0.416x +3.86%
2018-12-31 R$1.75 Billion
≈ $343.37 Million
R$701.49 Million
≈ $137.64 Million
0.401x +29.17%
2017-12-31 R$1.71 Billion
≈ $334.85 Million
R$529.61 Million
≈ $103.92 Million
0.310x -11.67%
2016-12-31 R$1.54 Billion
≈ $301.34 Million
R$539.57 Million
≈ $105.87 Million
0.351x +57.78%
2015-12-31 R$1.66 Billion
≈ $324.83 Million
R$368.63 Million
≈ $72.33 Million
0.223x +22.60%
2014-12-31 R$1.57 Billion
≈ $308.64 Million
R$285.71 Million
≈ $56.06 Million
0.182x +46.38%
2013-12-31 R$1.69 Billion
≈ $331.42 Million
R$209.59 Million
≈ $41.12 Million
0.124x +26.71%
2012-12-31 R$1.71 Billion
≈ $334.73 Million
R$167.05 Million
≈ $32.78 Million
0.098x +9.49%
2011-12-31 R$1.63 Billion
≈ $320.20 Million
R$145.96 Million
≈ $28.64 Million
0.089x -19.86%
2010-12-31 R$1.01 Billion
≈ $198.53 Million
R$112.92 Million
≈ $22.16 Million
0.112x +289.62%
2009-12-31 R$838.97 Million
≈ $164.62 Million
R$24.03 Million
≈ $4.72 Million
0.029x -93.99%
2008-12-31 R$151.84 Million
≈ $29.79 Million
R$72.40 Million
≈ $14.21 Million
0.477x -39.20%
2007-12-31 R$101.35 Million
≈ $19.89 Million
R$79.48 Million
≈ $15.60 Million
0.784x +16.44%
2006-12-31 R$105.91 Million
≈ $20.78 Million
R$71.33 Million
≈ $14.00 Million
0.673x --

About Fleury S.A.

SA:FLRY3 Brazil Diagnostics & Research
Market Cap
$1.57 Billion
R$7.99 Billion BRL
Market Cap Rank
#7202 Global
#73 in Brazil
Share Price
R$14.69
Change (1 day)
-0.74%
52-Week Range
R$12.62 - R$17.95
All Time High
R$26.18
About

Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides health management services, such as telemedicine; orthopedic medicine services; laboratory support; toxicological exam; preventive, integrated solutions, and cli… Read more